Efficacy and safety of ledipasvir/sofosbuvir versus elbasvir/grazoprevir in treatment of genotype 1b chronic hepatitis C
10.3760/cma.j.issn.1674-2397.2022.02.005
- VernacularTitle:来迪派韦/索磷布韦对比艾尔巴韦/格拉瑞韦治疗基因1b型慢性丙型肝炎疗效分析
- Author:
Haiyan CHEN
1
;
Xiaofeng LI
;
Zhaowei TONG
;
Jianfeng ZHONG
;
Qingqiu ZENG
;
Xianshan ZHANG
;
Weihong WANG
Author Information
1. 湖州市中心医院感染科 313000
- Keywords:
Hepatitis, chronic;
Gene type 1b;
Direct antiviral drugs;
Ledipasvir/sofosbuvir;
Elbasvir/grazoprevir
- From:
Chinese Journal of Clinical Infectious Diseases
2022;15(2):119-124
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the clinical efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) and elbasvir/grazoprevir (EBR/GZR) in treatment of patients with chronic hepatitis C (CHC).Methods:The clinical data of 143 patients with genotype 1b CHC treated in Huzhou Central Hospital from January 2020 to December 2021 were retrospectively analyzed, including 74 cases treated with LDV/SOF and 69 cases treated with EBR/GZR. The virological response after 4 and 12 weeks of treatment and 12wk after drug withdrawal was determined; and the serological and liver inflammation indexes before and after treatment in two groups were compared. SPSS 25.0 software was used for statistical analysis of the data.Results:The virological response rates of the LDV/SOF group and EBR/GZR group were 97.30% and 98.55%, 98.65% and 100.00%, 97.30% and 98.55% after 4 and 12 weeks of treatment and 12 weeks after the end of treatment, respectively (all P > 0.05). At the end of treatment, the liver inflammation indexes ALT, AST and GGT in the two groups were significantly lower than the baseline levels ( Z=-7.470 and -6.974, -9.757 and -6.832, -3.578 and -4.054, P<0.01). Adverse reactions in both groups were mild, and no serious adverse events occurred. Conclusion:Both LDV/SOF and EBR/GZR have good clinical efficacy in the treatment of genotype 1b CHC patients. And the patients are well tolerated.
